Perfusion processes can attractive for biologics drug manufacturing; however, obstacles remain.
Rene Gantier, Ph.D.
Advertisement
Articles by Rene Gantier, Ph.D.
Advertisement
Latest Updated Articles
- Going from Fed-Batch to Perfusion
Published: July 1st 2017 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
2
Biotech Equipment Market to Approach $144B by 2030: Implications for Pharma R&D
3
Everything to Know About Cell and Gene Therapy in 2025
4
Strategies for Building Tech Talent in the Biopharma Industry (Part 4)
5
